Santen Pharmaceutical Co., Ltd.

TSE:4536.T

1749 (JPY) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 301,965279,037266,257249,605241,555234,026224,942199,096195,291161,831148,663119,066114,416110,812110,594101,618103,394100,48598,39792,696
Cost of Revenue 138,089112,950109,67198,22194,83190,76486,37874,96672,82956,37358,10441,50135,38534,43634,71035,94736,51335,48334,53433,709
Gross Profit 163,876166,087156,586151,384146,724143,262138,564124,130122,462105,45890,55977,56579,03176,37675,88465,67166,88165,00263,86358,987
Gross Profit Ratio 0.5430.5950.5880.6060.6070.6120.6160.6230.6270.6520.6090.6510.6910.6890.6860.6460.6470.6470.6490.636
Reseach & Development Expenses 24,70328,29726,37724,11223,34123,75924,39822,78619,99017,47719,04016,71900000000
General & Administrative Expenses 91,52996,25784,49979,55473,36071,27368,78862,19359,40648,89337,353000000000
Selling & Marketing Expenses -4,25900000015,95015,23812,2236,751000000000
SG&A 87,27096,25784,49979,55473,36071,27368,78862,19359,40648,89344,10436,16400000000
Other Expenses 009,82434,80216,4883,1326,6876,672-37,1133,714154156881833720861987455223245
Operating Expenses 111,973169,177120,700138,468113,18998,16499,87391,65142,28370,08463,14452,88352,29845,63646,24450,17746,51044,58942,86840,003
Operating Income 51,903-3,09035,88612,91733,53545,09838,69132,47980,18035,37427,41424,68126,73330,73829,64015,49420,37020,41220,99518,982
Operating Income Ratio 0.172-0.0110.1350.0520.1390.1930.1720.1630.4110.2190.1840.2070.2340.2770.2680.1520.1970.2030.2130.205
Total Other Income Expenses Net -14,454-41,099-259-41,090-7,7691,727570-657-710489-5219101,058334-1,030329111626-654-548
Income Before Tax 37,449-5,79935,61612,41832,09143,11739,26131,82279,47035,86326,89325,59127,79131,07428,61015,82320,48221,03920,34118,436
Income Before Tax Ratio 0.124-0.0210.1340.050.1330.1840.1750.160.4070.2220.1810.2150.2430.280.2590.1560.1980.2090.2070.199
Income Tax Expense 3,1719,1848,4275,77310,37711,1744,0008,76826,09711,8319,7839,07010,6309,7419,8875,7007,8327,8927,3207,412
Net Income 26,642-14,94827,2186,83023,61831,94335,26123,05453,37324,03217,10916,52017,16021,33318,72210,12312,65013,14713,02211,022
Net Income Ratio 0.088-0.0540.1020.0270.0980.1360.1570.1160.2730.1490.1150.1390.150.1930.1690.10.1220.1310.1320.119
EPS 72.59-38.5868.0717.159.1678.6486.7652.96128.9958.1847.7839.1639.3949.9444.0223.8229.2330.3230.0525.17
EPS Diluted 72.37-38.5867.9717.0659.0178.4186.4552.76128.4157.9347.6339.139.3549.8843.9723.7929.1930.263025.14
EBITDA 70,08112,94953,88030,67451,05756,96750,59143,26990,30043,10032,01828,89730,75134,49432,87620,20725,42025,62326,28823,769
EBITDA Ratio 0.2320.0460.2020.1230.2110.2430.2250.2170.4620.2660.2150.2430.2690.3110.2970.1990.2460.2550.2670.256